The FIT Test: Home Stool Screening That Actually Works

The envelope is smaller than a paperback. Inside: a plastic tube with a little brush, an instruction sheet, and a prepaid mailer. Millions of Americans receive one every year, and a surprising number let it sit in a drawer next to the spare keys, half-meaning to get to it.

That drawer is worth opening. Colorectal cancer is the second-leading cause of cancer death in the United States when men and women are counted together, yet it is one of the few cancers we can reliably catch before symptoms appear. The catch has always been the screening itself: colonoscopy works, but the prep, the sedation, the day off work all give people reasons to postpone.

The kit in the envelope removes those reasons. It takes about two minutes, in your own bathroom, and the science behind it is better than most people assume. Here is what it can do, what it can’t, and where the whole system tends to break down.

What is the FIT test, exactly?

FIT stands for fecal immunochemical test. It screens for colorectal cancer by looking for occult blood in stool, meaning blood present in amounts far too small to see. You collect a tiny sample at home, seal it in a tube, and send it to a lab, where an antibody-based assay checks for human hemoglobin.

The logic rests on how colorectal cancer behaves. Most cases develop slowly from polyps over roughly 10 to 15 years, and both polyps and early tumors tend to have fragile surface blood vessels that leak intermittently. FIT is tuned to catch that leak long before you would ever notice anything.

According to the CDC, about 150,000 Americans are diagnosed with colorectal cancer each year, and screening from age 45 to 75 is recommended for adults at average risk. FIT is one of the officially endorsed options, done once a year. It is not a diagnostic test and it does not tell you whether you have cancer; it sorts people into two groups, those who need a closer look by colonoscopy and those who can simply repeat the test in a year.

That distinction matters more than any other fact in this article. FIT is a filter, not a verdict, and every result should be read that way.

How does FIT find blood you can't see?

The chemistry is genuinely elegant. FIT uses antibodies engineered to bind globin, the protein portion of human hemoglobin. When a lab technician processes your sample, those antibodies latch onto any human blood protein present and generate a measurable signal, typically reported in micrograms of hemoglobin per gram of stool.

Two design features make this smarter than older stool tests. First, the antibodies recognize only human hemoglobin, so a rare steak or a serving of blood sausage cannot trigger a false alarm the way it could with the older chemical-based test. Second, globin is digested and destroyed as it passes through the stomach and small intestine. Blood from a nosebleed you swallowed, or from higher in the digestive tract, largely breaks down before it reaches the colon. What survives intact is blood that entered the picture late, in the colon or rectum, which is exactly where colorectal cancers and polyps live.

The amounts involved are minuscule. A typical laboratory cutoff sits around 20 micrograms of hemoglobin per gram of stool, a quantity invisible to the eye and undetectable by anything except an immunoassay. That sensitivity is the whole point: by the time bleeding is visible in the toilet, screening has already been outrun, and the conversation shifts from prevention to diagnosis.

Is a FIT test as good as a colonoscopy?

Honest answer: not test-for-test, but the comparison is less lopsided than most people think, because the two are playing different games.

Colonoscopy examines the entire colon directly, finds cancers and precancerous polyps in the same session, and removes polyps on the spot. That prevention step is something no stool test can do, and it is why colonoscopy needs repeating only every 10 years after a normal exam. FIT, by contrast, checks a single snapshot of stool for blood. A one-time FIT will detect most cancers present that year, but it misses a majority of precancerous polyps, which bleed less consistently than tumors.

The equalizer is repetition. FIT is designed as an annual program, and a polyp or early cancer that stays quiet one year has multiple chances to be caught in later rounds. Modeling studies used by U.S. guideline groups project that yearly FIT with proper follow-up delivers life-years gained in the same neighborhood as a 10-year colonoscopy strategy for average-risk adults.

There is one non-negotiable clause in that sentence: with proper follow-up. A positive FIT that never leads to a colonoscopy protects no one. In my reading of the evidence, the best screening test is not the one with the highest sensitivity on paper. It is the one you will actually complete, year after year, including the follow-up when it counts.

How accurate is FIT? The honest numbers

A widely cited meta-analysis published in the Annals of Internal Medicine, pooling 19 studies, found that a single FIT detects about 79 percent of colorectal cancers, with specificity around 94 percent. Estimates used in U.S. screening guidance land in a similar range, roughly 74 to 80 percent sensitivity for cancer per round.

Translate that: if 100 people with colorectal cancer each did one FIT, roughly 74 to 80 would test positive and about 20 to 26 would slip through that year. That sounds alarming until you remember the annual design. A cancer missed this year usually bleeds more as it grows, raising the odds of detection at the next round while the disease is often still treatable.

The numbers for precancerous growths are humbler. FIT catches only about a quarter to a third of advanced adenomas, the polyps most likely to progress. This is FIT’s real weakness, and the reason repetition is built into the strategy rather than tacked on.

Specificity of 94 percent means false alarms happen, too: roughly 4 to 8 percent of average-risk people testing in a given round come back positive, and most of them will not have cancer. Hemorrhoids, anal fissures, inflammation, and benign polyps all bleed. Accuracy figures only tell you how the test performs; what happens after the result determines whether the performance matters.

How do you take a FIT test at home?

The process is simpler than assembling most furniture, and kits vary only in small details. A typical sequence looks like this:

• Catch the stool before it touches toilet water. Kits usually include a paper collection sheet or flushable tray that sits across the bowl.
• Open the sample tube and use the attached brush or probe to scrape a small amount from the surface of the stool. You need far less than people expect, roughly what clings to the tip of the probe.
• Click the probe back into the tube, which contains a stabilizing liquid, and tighten it. Do not reopen it.
• Label the tube with the collection date. Labs use this to confirm the sample is fresh enough to analyze.
• Mail it back promptly in the prepaid envelope or drop it off, ideally within a day or two, following your kit’s instructions.

Results typically arrive within a week or two, reported through your clinician or a patient portal. Two practical notes: avoid collecting during your menstrual period or while a hemorrhoid is actively bleeding, since either can cause a positive result that has nothing to do with your colon. Waiting a few days solves the problem. And read your specific kit’s instructions even if you have done this before; small differences between brands of kits trip up more samples than the collection itself.

Do you need to change your diet or medications first?

No, and this is one of FIT’s quiet superpowers. Because the test uses antibodies specific to human hemoglobin, animal blood in food cannot fool it. You can eat red meat the night before. Vitamin C, horseradish, and raw vegetables, all of which could distort the older guaiac-based stool test, do not interfere either.

The older test, called gFOBT, works through a chemical reaction with heme and required a genuinely annoying regimen: several days avoiding red meat, certain produce, and high-dose vitamin C, plus multiple stool samples collected on different days. Studies of screening programs consistently showed that these hoops lowered completion rates. FIT eliminated the hoops, and participation climbed accordingly; that behavioral improvement is a real part of why major screening programs, including the NHS bowel screening program in the United Kingdom, moved to FIT.

One nuance deserves plain language. Some common blood-thinning and anti-inflammatory medicines can increase minor gastrointestinal bleeding, and researchers have studied whether they raise false-positive rates. The evidence is mixed, and mainstream guidance generally does not require stopping any medicine before a FIT. Never stop a prescribed medication for a screening test on your own. If you take something that affects bleeding, mention it to your clinician; they will almost always tell you to proceed exactly as you are.

What if your FIT test is positive?

One thing happens next, and only one: a colonoscopy. A positive FIT means the lab detected human blood above the reporting threshold, and the source needs to be found by looking directly at the colon. There is no scenario in mainstream medical guidance where the right response is to simply repeat the FIT and hope for a negative.

That repeat-and-hope instinct is worth calling out because it is common and quietly dangerous. Polyps and early cancers bleed intermittently. A second FIT that comes back negative does not cancel the first one; it may simply have sampled a quiet day. Once a FIT is positive, the stool-testing phase of screening is over and the diagnostic phase begins.

Timing matters more than most people realize. Research on large screening populations has found that people who delayed follow-up colonoscopy beyond roughly 9 to 12 months after a positive FIT had higher rates of colorectal cancer and more advanced-stage disease at diagnosis than those scoped within a few months. Blood in the stool does not expire, but the window for catching disease early can.

Practically: call your clinician when the result arrives, ask for a colonoscopy referral, and put the date on the calendar within the next few weeks if scheduling allows. If cost or access is a barrier, say so out loud at that appointment; screening programs and clinics routinely have pathways for exactly this situation, and follow-up after a positive test is where they concentrate their effort.

A positive FIT usually isn't cancer, here's the math

Take a breath before you spiral, because the arithmetic is genuinely reassuring. In average-risk screening populations, roughly 4 to 8 percent of FITs come back positive in a given round. Among those positives, colonoscopy typically finds cancer in the low single digits, on the order of 1 in 20 to 1 in 25 people. The most common findings are far less dire.

What actually turns up behind a positive FIT, in rough order of frequency:

• Nothing identifiable at all, or minor irritation of the colon lining
• Hemorrhoids or anal fissures, which bleed easily and are benign
• Small, low-risk polyps that are removed during the colonoscopy itself
• Advanced adenomas, precancerous polyps found in roughly a quarter to a third of positive cases, also removed on the spot
• Cancer, in a small minority, and often at an earlier, more treatable stage than cancers found after symptoms appear

Notice something about that list: several of the outcomes are wins. Finding and removing an advanced adenoma is the screening system working exactly as designed, intercepting disease before it starts. Even the cancer scenario is the version of that diagnosis you would choose if you had to choose one, because stage at detection strongly shapes what treatment looks like.

So a positive FIT is a flag, not a forecast. It earns your prompt attention. It does not earn your panic, and it should never earn your avoidance.

What is a good FIT test score?

People search this constantly, and the honest answer is that for most patients there is no score to optimize. In the United States, FIT results are almost always reported as a binary: negative or positive, based on whether hemoglobin in the sample crossed the laboratory’s cutoff. A common threshold is around 20 micrograms of hemoglobin per gram of stool, though manufacturers and labs vary.

Behind that binary sits a real number, because modern FITs are quantitative. Screening programs in other countries use this openly; the NHS bowel screening program, for instance, applies a defined micrograms-per-gram cutoff to decide who is invited for colonoscopy, and researchers have shown that higher hemoglobin concentrations correlate with higher likelihood of significant findings. Someone whose result barely crosses the threshold is statistically less likely to have serious disease than someone far above it.

Here is why that should not change your behavior. The threshold exists precisely to draw the action line, and everyone above it gets the same next step: colonoscopy. A “barely positive” result still carries meaningfully elevated risk compared with a negative, and intermittent bleeding means a single low reading may understate what is there. Conversely, a negative result is not a grade to be proud of; it is simply a ticket to retest next year.

If your report does include a number and you are curious, ask your clinician what cutoff the lab used. Treat the number as context, never as a loophole.

Why doing it every year is the whole point

A single FIT is a decent test. An annual FIT habit is an excellent screening program, and the difference between those two sentences is where most of the benefit lives.

The math compounds in your favor. If one round detects about 75 to 80 percent of cancers, two consecutive annual rounds catch the large majority of what the first missed, because a growing lesion tends to bleed more over time. Precancerous polyps, which a single FIT often misses, get 10 to 15 years’ worth of annual chances to reveal themselves before they become dangerous. Modeling used by U.S. guideline panels shows that faithful yearly FIT narrows most of the gap with the 10-year colonoscopy strategy.

The failure mode is equally clear. Studies of real-world screening repeatedly find that many people complete one FIT and never do another, which converts a program-level strategy into a one-time coin flip. A FIT done once in your late forties and never repeated offers only a fraction of the protection the guidelines assume.

My strong opinion, grounded in that evidence: treat FIT like a birthday, not a decision. Anchor it to a fixed month, set the calendar reminder, and remove the annual deliberation entirely. Many health systems will mail kits automatically once you are enrolled; say yes to that. The people FIT protects best are not the ones who chose it most enthusiastically. They are the ones who made it boring and automatic.

Who should use FIT, and who needs a colonoscopy instead

FIT is built for one population: adults at average risk of colorectal cancer, with no symptoms, generally between ages 45 and 75. The U.S. Preventive Services Task Force lowered the starting age from 50 to 45 in 2021, a response to rising colorectal cancer rates in adults under 50. For people 76 to 85, guidance shifts to an individualized conversation weighing health status and prior screening history.

Average risk means none of the following apply to you. If any do, FIT is generally not your test, and colonoscopy on a personalized schedule is the standard path:

• A first-degree relative, meaning a parent, sibling, or child, who had colorectal cancer or advanced polyps, especially before age 60
• A personal history of colorectal cancer or precancerous polyps
• Inflammatory bowel disease, meaning Crohn’s disease or ulcerative colitis
• A known or suspected hereditary syndrome such as Lynch syndrome or familial adenomatous polyposis
• A history of abdominal or pelvic radiation for a prior cancer

The reasoning is straightforward. Higher-risk people need earlier screening, shorter intervals, and the polyp-removal capability only colonoscopy provides. A stool test’s miss rate that is acceptable at average risk becomes harder to justify when baseline risk is several times higher.

One more exclusion that surprises people: symptoms. FIT is a screening test for people who feel fine. If you have rectal bleeding, persistent bowel changes, or unexplained anemia, you need diagnostic evaluation, not a screening kit, and a negative FIT in that situation should not reassure anyone.

FIT vs. gFOBT vs. stool DNA vs. colonoscopy: how the options compare

Four screening approaches dominate the conversation for average-risk adults, and they trade off convenience, frequency, and what they can actually find. Guideline groups consider all of them legitimate choices; the differences show up in the fine print.

Test	How often	What it detects	Prep or restrictions	If positive
FIT	Every year	Hidden human blood via antibodies	None	Colonoscopy
gFOBT (older stool test)	Every year	Blood via a chemical reaction with heme	Dietary restrictions and multiple samples over several days	Colonoscopy
Multi-target stool DNA test	Every 1 to 3 years, typically 3	Hidden blood plus altered DNA shed by abnormal cells	None, but requires a full stool sample	Colonoscopy
Colonoscopy	Every 10 years if normal	Polyps and cancer directly; removes polyps in the same session	Full bowel prep, sedation, escort home	Not applicable; it is the follow-up

A few honest footnotes. The stool DNA test is somewhat more sensitive than FIT for cancer and advanced polyps in a single round, but it also produces more false positives, sending more cancer-free people to colonoscopy. The gFOBT still appears in guidelines but has largely been superseded; if you are offered a stool test today, it is very likely a FIT. And flexible sigmoidoscopy and CT colonography exist as additional options in U.S. guidance, though they are used less often in practice. The consistent thread across every row of that table: all roads from a positive stool test lead to colonoscopy.

Mistakes that can skew your FIT result

Labs reject a meaningful share of mailed-in FIT samples, and near-misses that get processed anyway can nudge results in either direction. The errors are mundane and almost entirely avoidable.

• Letting the sample sit too long. Hemoglobin degrades. Most kits want the tube mailed within a day or so of collection; a tube that rides around in a hot car for a week can turn a true positive into a false negative.
• Collecting from toilet water. Water dilutes and degrades the sample. Use the collection sheet or tray so the stool never takes a swim first.
• Skipping the date on the tube. Undated samples are a leading cause of lab rejection, which means doing the whole thing over.
• Collecting during menstruation or active hemorrhoid bleeding. Either can deposit blood that has nothing to do with your colon. Waiting a few days costs nothing and prevents an avoidable colonoscopy.
• Overfilling the tube. More is not better; the assay is calibrated for a tiny amount, and excess stool can compromise the result. The probe grooves hold all the lab needs.
• Treating a rejected or failed sample as a pass. An unprocessable kit is not a negative result. Request a replacement and repeat the collection.

None of this requires skill, only attention. Two minutes with the instruction sheet before you start, rather than mid-process with the tube already open, prevents essentially every item on this list.

When to see a doctor instead of waiting for a screening test

Screening exists for people who feel well. The moment symptoms enter the picture, the calculus changes entirely, and waiting for your next annual FIT, or trusting a recent negative one, is the wrong move. A screening test that misses 20 to 26 percent of cancers per round was never designed to rule out disease in someone with warning signs.

Contact your clinician promptly, regardless of your age or when you last screened, if you notice any of the following:

• Blood in your stool or on the toilet paper, whether bright red or dark and tarry
• A persistent change in bowel habits lasting more than a few weeks, such as new constipation, diarrhea, or narrower stools
• Ongoing abdominal pain, cramping, or bloating that does not resolve
• Unintended weight loss
• Persistent fatigue or a diagnosis of iron-deficiency anemia without an obvious cause
• A feeling that your bowel never empties completely

Most of these symptoms turn out to have benign explanations, hemorrhoids and irritable bowel patterns among the most common. But rising rates of colorectal cancer in adults under 50 have made one lesson painfully clear in the research literature: younger patients often experience long diagnostic delays because both they and their clinicians assume they are too young for this disease. You are not too young to mention blood in your stool. Say the words plainly at your appointment, ask what evaluation is appropriate, and do not let a normal screening result from last year close the conversation.

The bottom line: the best screening test is the one you finish

Strip away the acronyms and the FIT proposition is this: two minutes a year, in private, no prep, no needles, catching most colorectal cancers early enough to matter and building toward colonoscopy-level protection through sheer repetition. Decades of screening evidence, summarized by the CDC and others, show that regular screening by any recommended method lowers the risk of dying from colorectal cancer. The tragedy is that roughly 1 in 4 U.S. adults in the eligible age range still is not up to date with any screening at all.

FIT’s weaknesses are real and worth stating without flinching. It misses most precancerous polyps in any single round. It depends on annual discipline that many people do not sustain. And its entire value collapses if a positive result never becomes a colonoscopy, a failure that happens far more often than it should.

But those weaknesses share a common cure, and it is not a better test. It is follow-through. If the prep and logistics of colonoscopy have kept you unscreened for years, a FIT kit is not a compromise; it is a fully guideline-endorsed strategy that meets you where you are. Ask your clinician for one, or ask whether your health system mails them automatically. Then do the unglamorous thing the evidence keeps rewarding: put it on the calendar, every year, and answer a positive result with a scheduled appointment instead of a second opinion from the drawer.

Frequently asked questions

Is a FIT test as good as a colonoscopy?

Not in a single round, but done every year with reliable follow-up, FIT delivers protection in the same neighborhood. Colonoscopy inspects the whole colon and removes precancerous polyps on the spot, which no stool test can do. FIT misses most polyps in any one round but catches roughly 74 to 80 percent of cancers, and annual repeats give missed lesions multiple chances to be detected. Guideline groups endorse both strategies for average-risk adults.

What is the FIT test?

The fecal immunochemical test is an at-home colorectal cancer screening tool that detects hidden blood in stool using antibodies specific to human hemoglobin. You collect a tiny sample with a brush or probe, seal it in a tube, and mail it to a lab. It is recommended annually for average-risk adults, generally ages 45 to 75, and requires no bowel prep, sedation, or dietary restrictions.

What happens if your FIT test is positive?

You need a follow-up colonoscopy, and reasonably soon. A positive FIT means human blood was detected above the lab’s threshold, and colonoscopy is the only way to find the source. Most positives turn out to be hemorrhoids, benign polyps, or no identifiable cause; cancer is found in roughly 1 in 20 to 1 in 25 cases. Do not simply repeat the FIT, since intermittent bleeding can make a second test falsely reassuring.

What is a good FIT test score?

For most patients there is no score to aim for, because U.S. labs report FIT as simply negative or positive against a cutoff, commonly around 20 micrograms of hemoglobin per gram of stool. Higher hemoglobin concentrations do correlate with higher likelihood of significant findings, which is why some national programs use quantitative thresholds. But any result above the cutoff earns the same next step, a colonoscopy, regardless of how far above it falls.

Can hemorrhoids cause a positive FIT test?

Yes. Hemorrhoids and anal fissures bleed easily and are among the most common benign explanations for a positive FIT. That said, a positive result should never be written off as “probably just hemorrhoids” without a colonoscopy, because the test cannot distinguish where blood came from, and hemorrhoids and polyps can coexist. If a hemorrhoid is actively bleeding on collection day, wait a few days before sampling to avoid an avoidable false alarm.

How often should you do a FIT test?

Once a year, without gaps. The annual interval is built into the strategy: a single FIT misses roughly 20 to 26 percent of cancers and most precancerous polyps, and yearly repetition is what raises cumulative detection to a level comparable with other recommended screening approaches. Studies show many people complete one FIT and never repeat it, which sharply reduces the benefit. Anchoring the test to a fixed month each year helps make it automatic.

Do you need to stop any medicines or change your diet before a FIT?

Generally no. FIT’s antibodies react only to human hemoglobin, so red meat, vitamin C, and raw vegetables cannot distort the result the way they could with the older guaiac-based stool test. Mainstream guidance does not require stopping medicines beforehand, including those that affect bleeding, though you should mention any you take to your clinician. Never stop a prescribed medication on your own for the sake of a screening test.

At what age should you start FIT screening?

Age 45 for adults at average risk, according to current U.S. guidance, which lowered the starting age from 50 in 2021 in response to rising colorectal cancer rates in younger adults. Screening continues through age 75, with an individualized decision from 76 to 85. People with a family history of colorectal cancer or advanced polyps, prior polyps, or inflammatory bowel disease typically need to start earlier and use colonoscopy instead.

Can a FIT test miss cancer?

Yes. A single FIT misses roughly 20 to 26 percent of colorectal cancers, usually because tumors bleed intermittently and the sample caught a quiet day. This is precisely why the test is designed to be repeated every year, giving a missed lesion multiple chances at detection as it grows and bleeds more. A negative FIT also cannot rule out disease in someone with symptoms, who needs diagnostic evaluation rather than screening.

What is the difference between FIT and the older stool blood test (gFOBT)?

FIT uses antibodies that detect only human hemoglobin, while gFOBT uses a chemical reaction with heme that animal blood and certain foods can trigger. Practically, that means FIT needs no dietary restrictions and usually just one sample, whereas gFOBT required several days of food restrictions and multiple samples. FIT is also more sensitive for detecting cancers, which is why most modern screening programs, including national ones, have switched to it.

References

• CDC: Screening for Colorectal Cancer
• NHS: Bowel Cancer Screening

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.